The Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma.
Please note that following on from advice received from the company the timelines for this appraisal have been revised and we now anticipate that the appraisal will begin during late September 2020 when we will write to you about how you can get involved.